Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tvardi Therapeutics (69C) Stock Price & Analysis

1 Followers

69C Stock Chart & Stats

€1.10-€0.07(-5.98%)
At close: 5:30 PM GMT+1
€1€1.25€1.5Sep 10Nov 9
Day’s Range
EUR 1.10 - EUR 1.21
52-Week Range
EUR 0.57 - EUR 4.04
Previous Close
EUR 1.17
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 16.16M
Enterprise Value
EUR 2.20M
Total Cash (Recent Filing)
EUR 15.77M
Total Debt (Recent Filing)
EUR 145.00K
Price to Earnings (P/E)
―
Beta
-0.49
Next Earnings
Apr 06, 2027 (Est.)
EPS Estimate
-0.4
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Debt

Minimal reported debt reduces interest burden and near-term refinancing pressure, preserving more flexibility for research spending and clinical development. This is a durable balance-sheet advantage because current leverage is not the primary constraint on operations or capital allocation.

Improving Loss And Cash-Burn Trend

The reduction in cash burn and loss magnitude versus 2023–2024 indicates some improvement in financial discipline or spending efficiency. Although cash generation remains negative, a sustained improvement could extend operating runway and reduce the pace at which additional funding is required.

Targeted Drug Pipeline

A focused pipeline of oral small-molecule therapies gives Tvardi a defined development strategy around STAT3-driven cancer and fibrosis biology. Programs spanning HCC and IPF provide multiple potential clinical value paths if development succeeds, rather than relying on one indication alone.

Bears Say

Revenue Collapse

The decline to zero revenue removes an established operating funding source and shows that the company has not converted its development activities into recurring commercial or other reported revenue. This leaves future progress dependent on pipeline execution and financing capacity.

Persistent Losses And Cash Burn

Large ongoing losses are translating into substantial cash outflows, demonstrating that the business is not yet self-funding. Continued negative operating and free cash flow can consume available resources and increase dependence on external funding to maintain research and clinical programs.

Shrinking And Historically Unstable Balance Sheet

Meaningful asset contraction reduces the financial cushion available to support operations, while the history of negative equity indicates prior balance-sheet instability. Even with positive equity in the latest periods, this record weakens confidence in financial durability during continued losses.

Tvardi Therapeutics News

69C FAQ

What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was €0.57 and its highest was €4.04 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is €16.16M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s next earnings report is estimated for Apr 06, 2027 (not yet confirmed), which is in 143 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Nov 13, 2026. The company reported -€0.434 earnings per share for the quarter, beating the consensus estimate of -€0.516 by €0.082.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.40.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 13,338,943 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -€0.434 in its last earnings report, beating expectations of -€0.516. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Hedge funds hold Tvardi Therapeutics shares: the largest hedge-fund position in Tvardi Therapeutics is 1,686,442,656 shares, and hedge funds decreased their holdings by 21.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology